Prescient Therapeutics Advances PTX-100 in Phase 2a Study for CTCL

Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.

Prescient Therapeutics Limited has dosed the first patient in its Phase 2a clinical study of PTX-100, marking a significant milestone in the development of this potential treatment for Cutaneous T-Cell Lymphoma (CTCL). The study aims to enroll up to 40 patients across multiple sites in Australia, the USA, and Europe, focusing on evaluating the efficacy and safety of PTX-100. This advancement builds on positive results from earlier studies and highlights the company’s commitment to providing new treatment options for patients with relapsed or refractory CTCL, a rare cancer with limited current treatment options.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment, including targeted and cellular therapies. Their key product, PTX-100, is a first-in-class compound that inhibits the cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), disrupting oncogenic pathways and inducing cancer cell death. The company also develops innovative cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR, aimed at enhancing the effectiveness of adoptive cell therapies and enabling versatile T-cell targeting.

Average Trading Volume: 736,998

Technical Sentiment Signal: Buy

Current Market Cap: A$38.25M

For an in-depth examination of PTX stock, go to TipRanks’ Stock Analysis page.